ATE427303T1 - Benzoimidazolverbindungen - Google Patents

Benzoimidazolverbindungen

Info

Publication number
ATE427303T1
ATE427303T1 AT04816894T AT04816894T ATE427303T1 AT E427303 T1 ATE427303 T1 AT E427303T1 AT 04816894 T AT04816894 T AT 04816894T AT 04816894 T AT04816894 T AT 04816894T AT E427303 T1 ATE427303 T1 AT E427303T1
Authority
AT
Austria
Prior art keywords
benzoimidazole compounds
benzoimidazole
compounds
Prior art date
Application number
AT04816894T
Other languages
English (en)
Inventor
Kristen Arienti
J Breitenbucher
Daniel Buzard
James Edwards
Michael Hack
Haripada Khatuya
David Kindrachuk
Alice Lee
Jennifer Venable
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE427303T1 publication Critical patent/ATE427303T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/10Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ceramic Engineering (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT04816894T 2003-09-30 2004-09-29 Benzoimidazolverbindungen ATE427303T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50723603P 2003-09-30 2003-09-30

Publications (1)

Publication Number Publication Date
ATE427303T1 true ATE427303T1 (de) 2009-04-15

Family

ID=38952593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04816894T ATE427303T1 (de) 2003-09-30 2004-09-29 Benzoimidazolverbindungen

Country Status (21)

Country Link
US (10) US7432378B2 (de)
EP (1) EP1673348B1 (de)
JP (1) JP2007508011A (de)
KR (1) KR20060097024A (de)
CN (1) CN1886380B (de)
AR (1) AR045955A1 (de)
AT (1) ATE427303T1 (de)
AU (1) AU2004286933B2 (de)
BR (1) BRPI0414918A (de)
CA (1) CA2540704A1 (de)
DE (1) DE602004020364D1 (de)
ES (1) ES2323178T3 (de)
HR (1) HRP20060126A2 (de)
IL (1) IL174677A0 (de)
NO (1) NO20061950L (de)
NZ (1) NZ546259A (de)
PT (1) PT1673348E (de)
RU (1) RU2006110561A (de)
TW (1) TW200526637A (de)
WO (1) WO2005044807A2 (de)
ZA (1) ZA200603411B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045955A1 (es) * 2003-09-30 2005-11-16 Janssen Pharmaceutica Nv Compuestos benzoimidazolicos
MXPA06011021A (es) 2004-03-25 2007-04-13 Johnson & Johnson Compuestos de imidazol.
CA2572218C (en) 2004-06-30 2013-06-11 Janssen Pharmaceutica, N.V. Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
CA2609716C (en) 2005-05-26 2014-10-14 Tibotec Pharmaceuticals Ltd. Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile
EP2308840A1 (de) * 2005-06-30 2011-04-13 Prosidion Limited GPCR-Agonisten
CA2627722A1 (en) 2005-10-31 2007-06-21 Merck & Co., Inc. Cetp inhibitors
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US20090281120A1 (en) * 2005-12-12 2009-11-12 Ono Pharmaceutical Co., Ltd Bicyclic heterocyclic compound
WO2007117400A2 (en) * 2006-03-31 2007-10-18 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
CN101460483B (zh) * 2006-03-31 2013-05-08 詹森药业有限公司 作为组胺h4受体调节剂的苯并咪唑-2-基嘧啶和吡嗪
EP2010177A2 (de) * 2006-04-10 2009-01-07 Janssen Pharmaceutica N.V. Kombinationstherapie aus histaminrezeptor h1- und h4-antagonisten zur behandlung von juckreiz
FR2903311B1 (fr) * 2006-07-10 2012-06-15 Centre Nat Rech Scient Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
WO2009079001A1 (en) 2007-12-18 2009-06-25 Janssen Pharmaceutica N.V. Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor
EP2077263A1 (de) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Chinazoline und verwandte heterocyclische Verbindungen und ihre therapeutische Verwendung
EA019143B1 (ru) 2008-06-12 2014-01-30 Янссен Фармацевтика Нв Использование антагонистов н4-гистаминовых рецепторов для лечения послеоперационных спаек
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
CN103319459A (zh) 2008-06-30 2013-09-25 詹森药业有限公司 用于制备苯并咪唑-2-基嘧啶衍生物的方法
EP2350032B1 (de) * 2008-09-26 2016-05-25 Eisai R&D Management Co., Ltd. Benzoxazolverbindungen und anwendungsverfahren
WO2010036908A1 (en) * 2008-09-26 2010-04-01 Eisai R & D Management Co., Ltd. Use of benzoxazole compounds in the treatment of malaria
EP2201982A1 (de) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamin-H4-Rezeptorantagonisten zur Behandlung von Vestibularisstörungen
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
IT1395137B1 (it) * 2009-08-05 2012-09-05 Spider Biotech S R L Nuovi peptidi antipatogeni
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
EP2447263A1 (de) * 2010-09-27 2012-05-02 Bioprojet Benzazolderivate als Histamin-H4-Rezeptorliganden
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
DE102011122420B4 (de) 2011-12-24 2016-07-28 Volkswagen Aktiengesellschaft Verfahren zur Feststellung der Spannungsfreiheit in einem elektrischen Hochvolt-System und ein elektrisches Hochvolt-System
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
EP2671870A1 (de) * 2012-06-05 2013-12-11 Bioprojet Neuartige (aza)Benzhydryletherderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als H4-Rezeptorliganden für therapeutische Anwendungen
EP3378476A1 (de) 2012-06-08 2018-09-26 Sensorion H4-rezeptor-inhibitoren zur behandlung von tinnitus
NZ710640A (en) 2013-03-06 2019-03-29 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
KR102779499B1 (ko) * 2018-05-22 2025-03-12 니혼노야쿠가부시키가이샤 벤즈이미다졸 화합물 또는 그의 염류 및 해당 화합물을 함유하는 농원예용 살충 살진드기제 그리고 그의 사용 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2587029B1 (fr) * 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
JP2000516611A (ja) * 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー Mcp―1アンタゴニストとしての2―フェニルベンズイミダゾール誘導体
ES2234318T3 (es) 1998-11-03 2005-06-16 ABBOTT GMBH & CO. KG 2-fenil-benzimidazoles sustituidos, su preparacion y uso.
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6803362B2 (en) 2001-03-09 2004-10-12 Ortho-Mcneil Pharmaceutical Inc. Heterocyclic compounds
AR045955A1 (es) * 2003-09-30 2005-11-16 Janssen Pharmaceutica Nv Compuestos benzoimidazolicos

Also Published As

Publication number Publication date
US20090270611A1 (en) 2009-10-29
EP1673348B1 (de) 2009-04-01
WO2005044807A3 (en) 2005-08-11
ZA200603411B (en) 2007-07-25
US20090275748A1 (en) 2009-11-05
KR20060097024A (ko) 2006-09-13
CN1886380A (zh) 2006-12-27
WO2005044807A2 (en) 2005-05-19
US7723527B2 (en) 2010-05-25
DE602004020364D1 (de) 2009-05-14
AU2004286933B2 (en) 2010-11-18
RU2006110561A (ru) 2007-10-10
US20090270613A1 (en) 2009-10-29
US20090264647A1 (en) 2009-10-22
CN1886380B (zh) 2010-12-22
NZ546259A (en) 2009-05-31
US20090270366A1 (en) 2009-10-29
US20050070550A1 (en) 2005-03-31
US7705149B2 (en) 2010-04-27
IL174677A0 (en) 2006-08-20
BRPI0414918A (pt) 2006-11-07
TW200526637A (en) 2005-08-16
HRP20060126A2 (en) 2008-05-31
US7723526B2 (en) 2010-05-25
US20090264646A1 (en) 2009-10-22
PT1673348E (pt) 2009-05-11
US7705143B2 (en) 2010-04-27
US20090281307A1 (en) 2009-11-12
EP1673348A2 (de) 2006-06-28
US7662966B2 (en) 2010-02-16
CA2540704A1 (en) 2005-05-19
US20090247508A1 (en) 2009-10-01
NO20061950L (no) 2006-06-29
JP2007508011A (ja) 2007-04-05
ES2323178T3 (es) 2009-07-08
AR045955A1 (es) 2005-11-16
US7432378B2 (en) 2008-10-07
US7723359B2 (en) 2010-05-25
AU2004286933A1 (en) 2005-05-19
US20090264645A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
ATE427303T1 (de) Benzoimidazolverbindungen
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
IS8108A (is) Ný efnasambönd
DE602004020635D1 (de) Lanzetten betreffende verbesserungen
ATE363383T1 (de) Schlingenware
ATE368042T1 (de) Cephemverbindungen
IS7381A (is) Efnasambönd
AT502792A5 (de) Düsenanpressvorrichtung
IS7414A (is) Oxó-azabísýklísk efnasambönd
DK1622630T3 (da) P009368epdk1
IS8228A (is) Ný asetídínefnasambönd
NO20045659L (no) Forbindelser
DE10355350A8 (de) Elektromodul
IS8089A (is) Efnasambönd
IS8292A (is) Ný efnasambönd
ATA662003A (de) Trink-mundstück
ATE446959T1 (de) Chromenonindole
DK1633719T3 (da) Substituerede spirobenzazepiner
NO20031736D0 (no) Forbindelser
DE10394329D2 (de) Mäanderstent
ATE406350T1 (de) Prolinylarylacetamide
DE10329218B4 (de) Hotflue
SE0303452D0 (sv) New compounds
AT500001B8 (de) Münzscheideeinrichtung
ATA1802003A (de) Verbundhonring

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1673348

Country of ref document: EP

REN Ceased due to non-payment of the annual fee